
Solventum Corporation (SOLV) Stock Forecast & Price Target
Solventum Corporation (SOLV) Analyst Ratings
Bulls say
Solventum is a healthcare company that has caught the attention of analysts due to their "offensive M&A" strategy and capital allocation priorities, including a $1B share repurchase program. Despite the potential risks related to decreases in global healthcare spending and competitive pressure, the company has maintained strong performance, with first quarter results exceeding expectations and organic growth in all segments. This is reflected in their solid financials, with first quarter revenue at $2.007B (2.1% organic growth) and EPS at $1.48. Analysts have revised their estimates to account for this strong performance, with an increase in EPS to $6.59 for 2026 and $7.15 for 2027. With continued growth expected and a potential for further portfolio optimization, Solventum remains a solid investment opportunity with a "Buy" rating and a $93 price target.
Bears say
Solventum is a healthcare company that was spun out of 3M in 2024 with a global presence and a focus on medical technology segments. Despite a clear strategy to create value through divesting businesses, reducing debt, and solid execution, the company has faced challenges in certain segments resulting in underperformance. However, with a strong focus on improving operations and delivering growth, Solventum may present a long-term opportunity for investors.
This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.
Solventum Corporation (SOLV) Analyst Forecast & Price Prediction
Start investing in Solventum Corporation (SOLV)
Order type
Buy in
Order amount
Est. shares
0 shares